A Randomized, Phase II Trial of AEZS-108 in Chemotherapy Refractory Triple-negative (ER/PR/HER2-negative) LHRH-R Positive Metastatic Breast Cancer.

Reshma Mahtani; Joerg Engel; Andrew V. Schally; Stephanie Seitz; Olaf Ortmann; Stefan Gluck; Charles L. Vogel; Alberto J. Montero

A Randomized, Phase II Trial of AEZS-108 in Chemotherapy Refractory Triple-negative (ER/PR/HER2-negative) LHRH-R Positive Metastatic Breast Cancer.

Reshma Mahtani, Joerg Engel, Andrew V. Schally, Stephanie Seitz, Olaf Ortmann, Stefan Gluck, Charles L. Vogel, Alberto J. Montero

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting
Volume	29
State	Published - 2013

Disciplines

Medicine and Health Sciences

Cite this

A Randomized, Phase II Trial of AEZS-108 in Chemotherapy Refractory Triple-negative (ER/PR/HER2-negative) LHRH-R Positive Metastatic Breast Cancer. / Mahtani, Reshma; Engel, Joerg; Schally, Andrew V. et al.
In: Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting, Vol. 29, 2013.

Research output: Contribution to journal › Article › peer-review

@article{6fbb7bab67154850ac56570c3b14eb50,

title = "A Randomized, Phase II Trial of AEZS-108 in Chemotherapy Refractory Triple-negative (ER/PR/HER2-negative) LHRH-R Positive Metastatic Breast Cancer.",

author = "Reshma Mahtani and Joerg Engel and Schally, \{Andrew V.\} and Stephanie Seitz and Olaf Ortmann and Stefan Gluck and Vogel, \{Charles L.\} and Montero, \{Alberto J.\}",

note = "TPS11124 Background: Triple-negative breast cancer (TNBC) is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and human epidermal growth factor receptor-2 (HER2). It is characterized by its unique molecular profile, aggressive behavior, distinct patterns of metastasis, and lack of commercially available targeted therapies.",

year = "2013",

language = "American English",

volume = "29",

journal = "Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting",

}

TY - JOUR

T1 - A Randomized, Phase II Trial of AEZS-108 in Chemotherapy Refractory Triple-negative (ER/PR/HER2-negative) LHRH-R Positive Metastatic Breast Cancer.

AU - Mahtani, Reshma

AU - Engel, Joerg

AU - Schally, Andrew V.

AU - Seitz, Stephanie

AU - Ortmann, Olaf

AU - Gluck, Stefan

AU - Vogel, Charles L.

AU - Montero, Alberto J.

N1 - TPS11124 Background: Triple-negative breast cancer (TNBC) is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and human epidermal growth factor receptor-2 (HER2). It is characterized by its unique molecular profile, aggressive behavior, distinct patterns of metastasis, and lack of commercially available targeted therapies.

PY - 2013

Y1 - 2013

UR - https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.tps11124

M3 - Article

VL - 29

JO - Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting

JF - Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting

ER -

A Randomized, Phase II Trial of AEZS-108 in Chemotherapy Refractory Triple-negative (ER/PR/HER2-negative) LHRH-R Positive Metastatic Breast Cancer.

Disciplines

Other files and links

Cite this